ArticleFrontiers in immunology2026
Immunologic comparison of alpha-gal sensitized and non-sensitized groups from a community based sample.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Introduction: Alpha-gal syndrome is delayed, IgE-mediated hypersensitivity reaction to galactose-α-1, 3-galactose (alpha-gal), a carbohydrate epitope found in non-primate mammals. Sensitization is typically triggered by tick bites, with some sensitized individuals progressing to severe allergic reactions to red meat and other alpha-gal containing substances. Despite increasing clinical recognition, the immunologic mechanisms underlying alpha-gal sensitization remain poorly defined. Therefore, this article aimed to identify whether there are distinct immunologic differences between sensitized and non-sensitized groups sampled from a well-characterized, community-based cohort. Methods: Participants were matched by age, sex, and race/ethnicity then classified as sensitized (AG+) or non-sensitized (AG-) by laboratory criteria. Demographics, health history, and target concentration between the groups were compared using descriptive statistics, Wilcoxon tests, and multivariable logistic modeling. Results: AG+ participants (n=50) showed elevated concentrations of innate immune markers including CD163, Chitinase-3-like 1, gp130, and MMP2 (all p < 0.0001), and reduced levels of regulatory cytokines including IL-10, IL-12p40, IL-35, LIGHT, and interferons IFNα2 and IFNβ. Logistic regression identified three independent cytokine predictors of alpha-gal sensitization: IL-1α (OR = 2.75, 95% CI: 1.40-5.41, p = 0.004), IL-35 (OR = 0.22, 95% CI: 0.10-0.49, p < 0.001) and LIGHT (OR = 0.19, 95% CI: 0.05-0.75, p = 0.02). Discussion: Our findings showed distinct differences between AG+ and AG- groups, marked by increased pro-inflammatory signaling and decreased immune regulatory cytokines. These results support a model of immune dysregulation involving both the innate and adaptive arms of the immune system. Further research is needed to understand the functional role of these markers for those with clinical disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.